FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313178148> ?p ?o ?g. }

• W4313178148 abstract "<h3>Introduction/Background</h3> DCP-001 is a cell-based relapse vaccine developed to prevent disease recurrence following primary treatment. Trials in patients with acute myeloid leukemia have shown DCP-001 to be well-tolerated and interim results of an ongoing phase II study (ADVANCE II) revealed durable clinical responses. Interestingly, the tumor-associated antigens expressed by DCP-001 are shared across tumor types, most notably ovarian cancer (OC). Here, we present data on the anti-tumor efficacy of DCP-001 in humanized OC mice models and initial safety and tolerability data of the phase I clinical trial evaluating DCP-001 immunization in high-grade serous OC patients. <h3>Methodology</h3> Prior to initiation of a clinical trial, the efficacy of DCP-001 against OC cells was tested in a mouse model. Humanized mice were engrafted with SKOV3 cells and vaccinated when tumors reached an average volume of 75–100 mm³. Impact of DCP-001 vaccination was assessed on tumor growth. In the phase I trial, patients receive 6 immunizations with DCP-001; 4 bi-weekly vaccinations containing 25x10⁶ cells followed by 2 monthly boosters containing 10x10⁶ cells. Safety and tolerability is monitored up to 28 days after the last vaccination. <h3>Results</h3> In a pre-clinical humanized OC mouse model, DCP-001 vaccination led to significant reduction of tumor growth rate resulting in partial and complete tumor regressions. In patients, DCP-001 vaccination was well-tolerated and DCP-001 related adverse events were only mild to moderate and mostly related to local injection site reactions. Patients reported fatigue, diarrhea, headache, nausea, temperature elevation and generalized joint and muscle pain. No severe adverse events were observed. <h3>Conclusion</h3> Pre-clinical data in humanized OC mice demonstrated that DCP-001 reduces tumor growth and provided a rational for clinical therapeutic exploitation in OC patients. Initial data from the phase I trial demonstrates that DCP-001 is safe and well-tolerated and justifies continued exploration of this novel immunotherapy concept in OC patients." @default.
• W4313178148 created "2023-01-06" @default.
• W4313178148 creator A5002589149 @default.
• W4313178148 creator A5013586646 @default.
• W4313178148 creator A5015600152 @default.
• W4313178148 creator A5021272050 @default.
• W4313178148 creator A5037532651 @default.
• W4313178148 creator A5052230726 @default.
• W4313178148 creator A5056497648 @default.
• W4313178148 creator A5058771103 @default.
• W4313178148 creator A5076237543 @default.
• W4313178148 creator A5079990773 @default.
• W4313178148 creator A5088498222 @default.
• W4313178148 date "2022-10-01" @default.
• W4313178148 modified "2023-10-16" @default.
• W4313178148 title "2022-RA-1137-ESGO Use of an allogeneic, cell-based vaccine DCP-001 in high grade Serous Ovarian cancerpatients after primary treatment; A phase I clinical trial" @default.
• W4313178148 doi "https://doi.org/10.1136/ijgc-2022-esgo.648" @default.
• W4313178148 hasPublicationYear "2022" @default.
• W4313178148 type Work @default.
• W4313178148 citedByCount "0" @default.
• W4313178148 crossrefType "proceedings-article" @default.
• W4313178148 hasAuthorship W4313178148A5002589149 @default.
• W4313178148 hasAuthorship W4313178148A5013586646 @default.
• W4313178148 hasAuthorship W4313178148A5015600152 @default.
• W4313178148 hasAuthorship W4313178148A5021272050 @default.
• W4313178148 hasAuthorship W4313178148A5037532651 @default.
• W4313178148 hasAuthorship W4313178148A5052230726 @default.
• W4313178148 hasAuthorship W4313178148A5056497648 @default.
• W4313178148 hasAuthorship W4313178148A5058771103 @default.
• W4313178148 hasAuthorship W4313178148A5076237543 @default.
• W4313178148 hasAuthorship W4313178148A5079990773 @default.
• W4313178148 hasAuthorship W4313178148A5088498222 @default.
• W4313178148 hasBestOaLocation W43131781481 @default.
• W4313178148 hasConcept C126322002 @default.
• W4313178148 hasConcept C143998085 @default.
• W4313178148 hasConcept C197934379 @default.
• W4313178148 hasConcept C203014093 @default.
• W4313178148 hasConcept C22070199 @default.
• W4313178148 hasConcept C2778375690 @default.
• W4313178148 hasConcept C535046627 @default.
• W4313178148 hasConcept C71924100 @default.
• W4313178148 hasConcept C90924648 @default.
• W4313178148 hasConceptScore W4313178148C126322002 @default.
• W4313178148 hasConceptScore W4313178148C143998085 @default.
• W4313178148 hasConceptScore W4313178148C197934379 @default.
• W4313178148 hasConceptScore W4313178148C203014093 @default.
• W4313178148 hasConceptScore W4313178148C22070199 @default.
• W4313178148 hasConceptScore W4313178148C2778375690 @default.
• W4313178148 hasConceptScore W4313178148C535046627 @default.
• W4313178148 hasConceptScore W4313178148C71924100 @default.
• W4313178148 hasConceptScore W4313178148C90924648 @default.
• W4313178148 hasLocation W43131781481 @default.
• W4313178148 hasOpenAccess W4313178148 @default.
• W4313178148 hasPrimaryLocation W43131781481 @default.
• W4313178148 hasRelatedWork W2000054321 @default.
• W4313178148 hasRelatedWork W2073975292 @default.
• W4313178148 hasRelatedWork W2080987332 @default.
• W4313178148 hasRelatedWork W2107697672 @default.
• W4313178148 hasRelatedWork W2173699645 @default.
• W4313178148 hasRelatedWork W2502883985 @default.
• W4313178148 hasRelatedWork W2567400702 @default.
• W4313178148 hasRelatedWork W2789023463 @default.
• W4313178148 hasRelatedWork W2991006761 @default.
• W4313178148 hasRelatedWork W3120506851 @default.
• W4313178148 isParatext "false" @default.
• W4313178148 isRetracted "false" @default.
• W4313178148 workType "article" @default.